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Abstract 20 
Background: Symptoms of anxiety, irritability, and agitation (AIA) are prevalent among 21 
patients with bipolar I disorder (BD-I) mania with depressive symptoms, and could 22 
potentially be used to aid physicians in the identification of this more severe form of BD-23 
I. Using data from two clinical trials, the aims of this post hoc analysis were to describe 24 
the phenomenology of bipolar mania in terms of AIA and depressive symptoms, and to 25 
evaluate the influence of these symptoms on the likelihood of remission during 26 
treatment. 27 
Methods: Patients with a BD-I manic or mixed episode (Diagnostic and Statistical Manual 28 
of Mental Disorders IV criteria) were randomised to 3 weeks of double-blind treatment 29 
with asenapine, placebo, or olanzapine (active comparator). Anxiety was defined as a 30 
score of ≥3 on the Positive and Negative Syndrome Scale (PANSS) ‘anxiety’ item, 31 
irritability as a score of ≥4 on the Young Mania Rating Scale (YMRS) ‘irritability’ item, and 32 
agitation as a score of ≥3 on the YMRS ‘increased motor activity–energy’ item. 33 
Depressive symptoms were defined as a score of ≥1 on three or more individual 34 
Montgomery–Åsberg Depression Rating Scale (MADRS) items, or a MADRS Total score of 35 
≥20. 36 
Results: A total of 960 patients with BD-I were analysed, 665 with a manic episode and 37 
295 with a mixed episode. At baseline, 61.4% had anxiety, 62.4% had irritability, 76.4% 38 
had agitation, and 34.0% had all three AIA symptoms (‘severe AIA’); 47.3% had three or 39 
more depressive symptoms, and 13.5% had a MADRS Total score of ≥20. Anxiety, 40 
irritability, and severe AIA (but not agitation) were statistically significantly more 41 
common in patients with depressive symptoms. Patients with anxiety or severe AIA at 42 
baseline were statistically significantly less likely to achieve remission (YMRS Total <12). 43 
In general, remission rates were higher with asenapine and olanzapine than with 44 
placebo, irrespective of baseline AIA or depressive symptoms. 45 
Conclusions: Assessment of AIA symptoms in bipolar mania could enable physicians to 46 
identify patients with more severe depressive symptoms, allowing for appropriate 47 
3 
intervention. Assessment and monitoring of AIA may help physicians to predict which 48 
patients may be harder to treat. 49 
Trial registration: ClinicalTrials.gov NCT00159744, NCT00159796. Registered 8 50 
September 2005 (retrospectively registered). 51 
Keywords 52 
bipolar disorder, mixed features, depression, anxiety, irritability, agitation, remission  53 
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Background 54 
Bipolar I disorder (BD-I) is an illness that comprises more than just two discrete poles; 55 
between the extremes of ‘pure’ mania and ‘pure’ depression, patients can experience 56 
‘mixed’ states in which various manic and depressive symptoms are present at the same 57 
time. Mixed states were described by Kraepelin in the early 20th century, and have been 58 
well characterised and operationally defined in the hundred years since (Kraepelin 1921; 59 
Swann et al. 2013). The fourth edition of the Diagnostic and Statistical Manual of Mental 60 
Disorders (DSM-IV) defined a ‘mixed episode’ as the coexistence of the full 61 
symptomatology of a manic and a depressive episode – a restrictive, categorical 62 
approach that neglects those patients with subsyndromal depressive symptoms (Vieta 63 
and Valentí 2013; American Psychiatric Association 1994). Since the DSM-IV, studies 64 
have shown that this definition does not reflect clinical reality and that patients with 65 
bipolar disorder (as well as patients with major depressive disorder [MDD]) have a 66 
complex symptom presentation (Vieta and Valentí 2013; Targum and Nierenberg 2011). 67 
Consequently, the fifth edition of the DSM (DSM-5) changed to a dimensional approach 68 
for the diagnosis of BD-I (Vieta and Valentí 2013). The DSM-5 includes a ‘with mixed 69 
features’ specifier that applies to a manic or hypomanic episode with three or more 70 
depressive symptoms (or, alternatively, to a depressive episode with three or more 71 
manic symptoms) (American Psychiatric Association 2013). In a retrospective chart 72 
review, three times as many patients with bipolar disorder were diagnosed with mixed 73 
features using the DSM-5 criteria compared with the DSM-IV text revision (DSM-IV-TR) 74 
criteria for a mixed episode (Shim et al. 2015). In an observational study, around half of 75 
patients with DSM-IV bipolar mania did not meet the criteria for DSM-5 bipolar mania, 76 
due to the additional requirement of increased activity or energy levels (Machado-Vieira 77 
et al. 2017). However, 45% of these patients now met the DSM-5 criteria for a major 78 
depressive episode with mixed features, showing the value of the mixed features 79 
specifier for making diagnoses across the continuum of mood disorders (Machado-Vieira 80 
et al. 2017). 81 
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Patients with BD-I mixed states have a worse clinical course than those with ‘pure’ manic 82 
states, since they tend to experience more episodes, and since episodes are of longer 83 
duration (Swann et al. 2013). Mania with depressive symptoms is also associated with a 84 
high rate of comorbid conditions, such as anxiety disorders and substance abuse (Swann 85 
et al. 2013). These patients are harder to treat and physicians of patients meeting the 86 
DSM-5 criteria for mania ‘with mixed features’ report greater treatment dissatisfaction 87 
than do physicians of patients without mixed features (Swann et al. 2013; Young and 88 
Eberhard 2015). Furthermore, there is a higher risk of suicidality among patients with 89 
mixed features; these patients are more likely to have made at least one suicide attempt 90 
during their lifetime, and during their current manic episode, compared with patients 91 
without mixed features (Swann et al. 2013; Young and Eberhard 2015). Thus, the 92 
presence of depressive symptoms during a manic episode is indicative of a more severe 93 
form of BD-I. 94 
The symptoms observed in manic episodes and depressive episodes are not mutually 95 
exclusive, with anxiety, irritability, and agitation (AIA), for example, occurring in both 96 
mania and depression. Since they are not specific to either pole, AIA symptoms are not 97 
included in the DSM-5 ‘with mixed features’ specifier (Cassidy 2010; Koukopoulos et al. 98 
2013). (Anxiety is, however, covered by the DSM-5 ‘with anxious distress’ specifier 99 
[American Psychiatric Association 2013].) According to physicians, AIA symptoms show 100 
an increased prevalence, and greater severity, in patients with mixed features in BD-I 101 
mania compared with those without mixed features (Young and Eberhard 2015). 102 
Similarly, in an online survey, patients with mania with depressive symptoms self-103 
reported the combination of ‘anxiety or worry’ and ‘irritability or agitation’ more 104 
frequently than those without depressive symptoms (Vieta et al. 2014). A recent 105 
prospective study from the Stanley Bipolar Network found increased irritability in bipolar 106 
patients with mixed depression compared with pure depression (Miller et al. 2016). Due 107 
to their high frequency among such patients, AIA symptoms could potentially be used as 108 
indicators (albeit non-specific indicators) to aid physicians in the identification of patients 109 
whose mania is complicated by depressive symptoms. 110 
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Using data from two pivotal, randomised, placebo-controlled asenapine trials, the aims of 111 
the present post hoc analysis were (1) to describe the phenomenology of bipolar mania 112 
in terms of AIA and depressive symptoms, (2) to evaluate if the presence of AIA and 113 
depressive symptoms can be used to predict non-remission, and (3) to evaluate the 114 
effect of asenapine, placebo, and olanzapine on remission in patients with AIA, and in 115 
patients with depressive symptoms. 116 
Methods 117 
This was a post hoc analysis of patient-level data from two 3-week, randomised, placebo-118 
controlled trials (ARES 7501004 and ARES 7501005; ClinicalTrials.gov identifiers 119 
NCT00159744 and NCT00159796, respectively) of asenapine in patients with BD-I 120 
experiencing an acute DSM-IV manic or mixed episode (McIntyre et al. 2009, 2010). 121 
Olanzapine was included as active comparator. 122 
Study design and patients 123 
The two primary studies had identical designs, which have been described previously 124 
(McIntyre et al. 2009, 2010). In brief, eligible patients were aged ≥18 years with a 125 
current DSM-IV diagnosis of BD-I. Patients were required to have a manic or mixed 126 
episode that began in the 3 months prior to screening, a Young Mania Rating Scale 127 
(YMRS; Young et al. 1978) Total score of ≥20 at screening and baseline, and a 128 
documented history of at least one previous moderate-to-severe mood episode, with or 129 
without psychotic features. Patients were excluded if they had a primary diagnosis other 130 
than BD-I, a psychotic disorder, rapid-cycling bipolar disorder, or substance abuse or 131 
dependence. 132 
Eligible patients entered a single-blind placebo run-in (washout) period of up to 7 days in 133 
an inpatient treatment centre. Following the run-in period, patients were randomised in a 134 
2:1:2 ratio to 3 weeks of double-blind treatment with oral asenapine (20 mg on Day 1, 135 
flexible-dose 10 or 20 mg/day thereafter; dose divided across morning and evening), 136 
placebo, or olanzapine (15 mg on Day 1, flexible-dose 5–20 mg thereafter; once daily). 137 
Patients remained in the inpatient centre for at least the first 7 days of treatment, after 138 
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which they could complete the trial as outpatients if they were deemed stable and 139 
suitable for discharge by the investigator. Benzodiazepines (lorazepam ≤4 mg/day for 140 
agitation; temazepam ≤30 mg/day for insomnia; or others with comparable half-lives) 141 
were permitted for the first 7 days of treatment only. 142 
Assessments 143 
In the two primary studies, efficacy was assessed using psychiatric rating scales including 144 
the YMRS, the Clinical Global Impressions – Bipolar version (CGI-BP; Spearing et al. 145 
1997; Guy 1976), the Montgomery–Åsberg Depression Rating Scale (MADRS; 146 
Montgomery and Åsberg 1979), and the Positive and Negative Syndrome Scale (PANSS; 147 
Kay et al. 1987). YMRS and CGI-BP assessments were made at screening, baseline, and 148 
Days 2, 4, 7, 14, and 21 (or end of treatment). MADRS assessments were made at 149 
baseline, Day 7, and at Day 21 or study endpoint. 150 
In this post hoc analysis, the presence or absence of AIA symptoms at baseline was 151 
assessed using the following definitions. Anxiety was defined as a score of ≥3 (“mild”) on 152 
the PANSS anxiety item (item G2; possible score range from 1 “absent” to 7 “extreme”; 153 
Kay et al. 1987). Irritability was defined as a score of ≥4 (“irritable at times during 154 
interview, recent episodes of anger or annoyance on ward”) on the YMRS irritability item 155 
(item 5; possible score range from 0 “absent” to 8 “hostile, uncooperative; interview 156 
impossible”; Young et al. 1978). Agitation was defined as a score of ≥3 (“excessive 157 
energy, hyperactive at times, restless [can be calmed]”) on the YMRS increased motor 158 
activity–energy item (item 2; possible score range from 0 “absent” to 4 “motor 159 
excitement; continuous hyperactivity [cannot be calmed]”; Young et al. 1978). ‘Severe 160 
AIA’ was defined as meeting the above criteria for all three AIA symptoms. 161 
Two definitions were used, in separate analyses, for the presence of depressive 162 
symptoms at baseline: (1) a score of ≥1 on three or more individual MADRS items; (2) a 163 
MADRS Total score of ≥20. 164 
Two definitions were used, in separate analyses, for YMRS remission: (1) a YMRS Total 165 
score of <12 at endpoint (Day 21); (2) a YMRS Total score of <8 at endpoint (Day 21). 166 
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Safety and tolerability were assessed in the primary studies; please refer to the primary 167 
sources for these analyses (McIntyre et al. 2009, 2010). 168 
Statistical analyses 169 
This post hoc analysis was performed on the full analysis set (FAS), which comprised all 170 
randomised patients who took at least one dose of study medication, and had at least 171 
one valid post-baseline YMRS assessment. 172 
For baseline analyses of the incidence of AIA symptoms stratified by the number and 173 
severity of depressive symptoms, between-group comparisons were made using a chi-174 
squared test. Incidence of remission, stratified by the presence or absence of baseline 175 
AIA and depressive symptoms, was analysed using two criteria – YMRS Total score of 176 
<12, and YMRS Total score of <8, at Day 21 – also using a chi-squared test for between-177 
group comparisons. Due to repeated testing, a significance level of 0.01 was applied in 178 
the remission analyses (Bonferroni adjustment for multiplicity); a significance level of 179 
0.05 was applied elsewhere. A footnote on relevant comparisons indicates where the 180 
significance level is 0.01. 181 
The AIA parameters that were found to be statistically significant predictors of non-182 
remission were then examined using an analysis of covariance (ANCOVA), in order to 183 
determine the effects of treatment (asenapine, placebo, or olanzapine) on change in 184 
YMRS Total score over time. Between-group comparisons were made using a t-test. 185 
Results 186 
Disposition 187 
Across the two primary studies, a total of 977 patients were randomised and 976 were 188 
treated. The FAS comprised 960 patients (480 from each study), split into asenapine 189 
(n=372), placebo (n=197), and olanzapine (n=391) treatment groups. 190 
1. Baseline characteristics: phenomenology of bipolar mania in terms of 191 
AIA and depressive symptoms 192 
9 
Patient baseline demographic and clinical characteristics are presented in Table 1. 193 
Slightly over half of patients were male, and the majority were unemployed. The ratio of 194 
manic to mixed episodes of BD-I was approximately 7:3. On average, patients had 195 
pronounced mania at baseline (mean [SD] YMRS Total score of 28.9 [6.2] and CGI-BP 196 
Mania severity of 4.6 [0.8] – markedly ill), and mild depression (mean [SD] MADRS Total 197 
score of 11.3 [7.3] and CGI-BP Depression severity of 2.1 [1.3] – minimally ill). Patients 198 
were well matched between treatment groups for all measurements. 199 
[Table 1 goes here.] 200 
Overall, 589 patients (61.4%) had anxiety at baseline, 599 patients (62.4%) had 201 
irritability at baseline, and 733 patients (76.4%) had agitation at baseline. Severe AIA 202 
(i.e., all three AIA symptoms) was present in 326 patients (34.0%). The proportion of 203 
patients with each AIA symptom, and the overlap between symptoms, is shown in Figure 204 
1. 205 
[Figure 1 goes here.] 206 
Considering depressive symptoms, 454 patients (47.3%) had three or more depressive 207 
symptoms at baseline based on individual MADRS items, and 130 patients (13.5%) had a 208 
MADRS Total score of ≥20. 209 
Figure 2 shows the relationships between depressive symptoms and AIA symptoms at 210 
baseline. Anxiety and irritability were statistically significantly more common in patients 211 
with depressive symptoms at baseline, both for patients with three or more individual 212 
depressive symptoms, and for patients with a MADRS Total score of ≥20. Agitation, in 213 
contrast, was not more common in patients with depressive symptoms at baseline. 214 
Finally, severe AIA (all three symptoms) was statistically significantly more common in 215 
patients with depressive symptoms at baseline. 216 
[Figure 2 goes here.] 217 
2. Can the presence of AIA and depressive symptoms be used to predict 218 
non-remission? 219 
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As shown in Figure 3a, patients with anxiety at baseline were statistically significantly 220 
less likely to achieve remission than those without anxiety at baseline, according to both 221 
definitions of remission (YMRS Total score of <12 and <8 at Day 21). The presence of 222 
severe AIA at baseline also had a statistically significant negative effect on remission, 223 
when defined as a YMRS Total score of <12. The presence of agitation at baseline 224 
reduced the incidence of remission by 8–10 percentage points, but this did not meet the 225 
criteria for statistical significance. The only AIA symptom without a notable effect on 226 
remission was irritability. 227 
As shown in Figure 3b, the presence of three or more depressive symptoms at baseline 228 
reduced the incidence of remission by 6–9 percentage points, but this did not meet the 229 
criteria for statistical significance. In contrast, the presence of depressive symptoms 230 
defined by a MADRS Total score of ≥20 had no notable effect on remission rate. 231 
[Figure 3 goes here.] 232 
3. Effect of treatment on remission in patients with AIA and depressive 233 
symptoms 234 
With remission defined as a YMRS Total score of <12 at Day 21, remission rates were 235 
higher with asenapine and olanzapine than with placebo among patients with anxiety, 236 
irritability, agitation, or severe AIA at baseline, as shown in Figure 4a. With remission 237 
defined as a YMRS Total score of <8 at Day 21, remission rates were only higher than 238 
placebo with asenapine and olanzapine among patients with irritability or agitation at 239 
baseline. For patients with depressive symptoms at baseline, remission rates were 240 
generally higher with asenapine and olanzapine than with placebo, as shown in Figure 241 
4b. These differences were not tested for statistical significance. 242 
[Figure 4 goes here.] 243 
Since baseline anxiety and severe AIA were identified as statistically significant predictors 244 
of non-remission (see Figure 3a), stratified analyses according to feature present or not 245 
present were carried out, to determine the effect of treatment on change in YMRS Total 246 
score over time. As shown in Figure 5, asenapine and olanzapine produced a statistically 247 
significant benefit on YMRS Total score at the majority of time points among patients 248 
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with anxiety at baseline (Day 21 effect sizes: 0.33 for asenapine, and 0.34 for 249 
olanzapine). The benefits were even greater among patients without anxiety at baseline 250 
(Day 21 effect sizes: 0.76 for asenapine, and 0.95 for olanzapine). A statistically 251 
significant benefit on YMRS Total score was also observed at the majority of time points 252 
among patients with severe AIA at baseline (Day 21 effect sizes: 0.42 for asenapine, and 253 
0.45 for olanzapine). 254 
[Figure 5 goes here.] 255 
Discussion 256 
This post hoc analysis of two randomised, controlled trials revealed that symptoms of 257 
anxiety, irritability, and agitation were present in around two-thirds-to-three-quarters of 258 
patients with BD-I mania. In addition, around a third of patients had all three AIA 259 
symptoms. While different studies have defined the presence of AIA symptoms in 260 
different ways, there is agreement in the literature that AIA symptoms are common 261 
among patients with BD-I mania (Hantouche et al. 2006; Vieta et al. 2014; Young and 262 
Eberhard 2015). 263 
The present analysis also showed that half of patients with BD-I mania had at least three 264 
depressive symptoms, whereas less than one in seven patients had a MADRS Total score 265 
of ≥20. A previous post hoc analysis in the same dataset found that 4–34% of patients 266 
met proxy criteria for the DSM-5 ‘with mixed features’ specifier, depending on the 267 
severity cut-offs used (McIntyre et al. 2013a). In general, the incidence of depressive 268 
symptoms among bipolar disorder patients with mania is around 30–40%, though the 269 
incidence varies widely according to how the presence of depressive symptoms is defined 270 
(McElroy et al. 1992; Akiskal et al. 1998; Hantouche et al. 2006; Azorin et al. 2009; 271 
Vieta et al. 2014; Young and Eberhard 2015; McIntyre et al. 2015). In a prospective 272 
study of patients with bipolar hypomania, the likelihood of having depressive symptoms 273 
was significantly greater for women (72%) than for men (42%) (Suppes et al. 2005). 274 
With regard to the relationship between AIA and depressive symptoms, the analysis 275 
showed that anxiety, irritability, and the AIA combination – but not agitation alone – 276 
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were more common in patients with depressive symptoms at baseline. This replicates the 277 
findings of a naturalistic study, in which anxiety and irritability were more common in 278 
BD-I patients with three or more depressive symptoms, whereas agitation was not 279 
(Young and Eberhard 2015). Thus, anxiety and irritability, and the combination of all 280 
three AIA symptoms, could potentially be used as non-specific indicators, or ‘gateway 281 
symptoms’, to help psychiatrists identify bipolar mania with depressive symptoms 282 
(Eberhard and Weiller 2016). At present, the DSM-5 does not highlight or discuss AIA 283 
symptoms in the ‘with mixed features’ specifier section. Future iterations of the DSM may 284 
want to consider how to discuss the findings of this study and related studies in terms of 285 
the mixed specifier. While our findings are not definitive, given the retrospective nature 286 
of these analyses and limits of the studies themselves, they do highlight the need for 287 
further assessment of the best components to make up the mixed specifier for future 288 
DSM-5 editions. 289 
These results support the importance of assessing carefully any patient presenting with 290 
significant anxiety, irritability, and agitation for underlying symptoms of depression, 291 
especially during mania or hypomanic episodes. While it is routine practice to 292 
administer depression scales in some settings, this is not universal. The presence of 293 
these symptoms supports that it is a time to review carefully whether they herald less 294 
visible symptomology that could inform both clinical care and address patient concerns 295 
such as self-harm. As noted in a recent article by Solé and colleagues (2017) and 296 
consistent with the findings reported here, indicators of mixity may be key to 297 
appropriate treatment choices and addressing suicide prevention effectively (Solé et al. 298 
2017). 299 
Of interest, a recent pilot study examined the use of actigraphy to assess prediction for 300 
different bipolar clinical states including mania, depression, and mixed (Scott et al. 301 
2017). In this small sample with 24 hours of observation, the researchers were able to 302 
predict with 79% accuracy which state a subject was experiencing (Scott et al. 2017). 303 
It is to be hoped these types of objective measures may assist us to understand, 304 
prevent, and treat mixed symptoms more efficiently. 305 
 306 
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The presence of anxiety in patients with bipolar disorder has previously been associated 307 
with a longer time to remission (Feske et al. 2000). The present analysis extended this 308 
observation – showing that patients with anxiety or a combination of all three AIA 309 
symptoms are less likely to achieve remission than those without the corresponding 310 
symptom(s). Thus, these data support the notion that AIA symptoms identify a more 311 
severe or complicated phenotype of mania that is less likely to respond to treatment. 312 
Similarly, patients with three or more depressive symptoms were less likely to achieve 313 
remission, although this outcome did not meet the criteria for statistical significance. 314 
However, patients with a MADRS Total score of ≥20 showed similar remission rates to 315 
those below this depression threshold. The previous post hoc analysis in this same 316 
dataset also found that the remission rate (defined as a YMRS Total score of ≤12) was 317 
not influenced by the number or severity of depressive symptoms (with the exception of 318 
the most severely depressed patients, who showed a higher remission rate) (McIntyre et 319 
al. 2013a). It may be that those patients who are the most ill may also be the most 320 
responsive to the medications under study, and thus most likely to show a larger degree 321 
of improvement. 322 
In BD-I (unlike in MDD) there has been relatively little prior investigation into whether 323 
patient characteristics (including AIA) within an episode can affect treatment response 324 
and other health outcomes (Feske et al. 2000). A recent analysis showed that the 325 
presence of AIA symptoms raises the already high suicide risk among patients with BD-I 326 
mania with depressive symptoms (Eberhard and Weiller 2016). Additionally, a subtype of 327 
bipolar depression, characterised by anxiety and irritability among other symptoms, is 328 
associated with a greater likelihood of receiving government financial support, suggesting 329 
that this pattern of symptoms is particularly malign (Perich et al. 2016). From a clinical 330 
point of view, given the hazards proxied by AIA, clinicians should routinely probe for AIA, 331 
and should systematically target these symptoms with treatment. In MDD, for example, 332 
many physicians reserve adjunctive antipsychotics for use in patients presenting with 333 
agitation or irritability, among other symptoms (McIntyre and Weiller 2015). 334 
Furthermore, the 2015 update to the Florida Best Practice Psychotherapeutic Medication 335 
Guidelines provides different algorithms for the treatment of MDD according to the 336 
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presence or absence of mixed features (University of South Florida 2015); this is an 337 
unmet need for BD-I. 338 
In the present analysis, both asenapine and olanzapine demonstrated higher remission 339 
rates (defined as a YMRS score of <12) than placebo among patients with AIA 340 
symptoms. A more stringent definition of remission was also considered (a YMRS score of 341 
<8); remission rates were low (<25%) with this definition regardless of treatment, 342 
demonstrating the difficulty in reducing symptoms to this level over such a short time 343 
period. Asenapine and olanzapine also showed consistent benefits over placebo in terms 344 
of mean change from baseline in YMRS Total score among patients with anxiety and all 345 
three AIA symptoms. In general, second-generation antipsychotics are efficacious in the 346 
treatment of mixed episodes with predominant manic symptoms, and have been 347 
described as the treatment of choice in the management of bipolar disorder mixed states 348 
(Muralidharan et al. 2013; Fagiolini et al. 2015). In mania with DSM-5 mixed features, 349 
asenapine, aripiprazole, and olanzapine have been evaluated and have shown efficacy as 350 
potential treatment options (McIntyre et al. 2013a, 2013b; Tohen et al. 2014). 351 
In line with considerations of best treatment choices, a range of guideline efforts for the 352 
treatment of bipolar disorder have recently been developed (Stahl et al. 2017; 353 
Fountoulakis et al. 2016; Goodwin et al. 2016) or are in revision, such as the CANMAT 354 
guidelines (Yatham et al. 2013). The importance of the results reported in this present 355 
post hoc analysis are highlighted as the best definition for mixed symptoms is sought and 356 
the understanding of the implications for treatment and course of illness is developed. It 357 
is clear from both past and more recent efforts that mixed symptoms herald a more 358 
severe course of illness, but the optimal definition is still under enquiry (Swann et al. 359 
2013; Barbuti et al. 2017). 360 
This present study is limited in that it is a post hoc analysis of studies that were not 361 
designed for this purpose. In particular, as these were regulatory studies, patients 362 
with current suicidality or complex comorbidities were excluded from study entry, 363 
thus limiting generalizability. In terms of study design, participants were inpatients for 364 
at least the first week of treatment, which may have selected for agitation. The results 365 
may also have been influenced by the use of benzodiazepines for agitation. 366 
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Benzodiazepines were not permitted beyond Day 7 of treatment; however, 131 patients 367 
(13.6%) in the FAS received one or more doses of benzodiazepines beyond Day 7. The 368 
use of proxies for AIA and depressive symptoms was another limitation of the analysis – 369 
especially for agitation, which was based on the YMRS increased motor activity–energy 370 
item because no agitation item was available. Since irritability and agitation were based 371 
upon YMRS items, they were not independent with regard to YMRS remission. It is 372 
important to keep in mind that this proxy for depression symptoms (MADRS ≥3), and 373 
thus potential mixed symptoms, does not itself assess for the DSM-5 Mixed Specifier 374 
criteria and must be viewed as a limit of the study design. Finally, the analysis does not 375 
rule out the possibility of pseudospecificity: that AIA and depressive symptoms are 376 
discrete, overlapping phenomena. 377 
Conclusions 378 
Assessment of AIA symptoms in bipolar mania could enable physicians to identify 379 
patients with more severe depressive symptoms (who may be at increased risk of 380 
suicide), allowing for appropriate intervention. Furthermore, assessment and monitoring 381 
of AIA may help physicians to predict which patients may be harder to treat. 382 
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Tables 559 
Table 1 560 
Baseline demographic and clinical characteristics 561 
 Asenapine 
(n=372) 
Placebo 
(n=197) 
Olanzapine 
(n=391) 
Total 
(N=960) 
Male, n (%) 203 (54.6) 98 (49.7) 230 (58.8) 531 (55.3) 
Age (years), median (range) 40 (18–76) 39 (18–69) 39 (18–67) 39 (18–76) 
Unemployed, n (%) 270 (72.6) 139 (70.6) 285 (72.9) 694 (72.3) 
DSM-IV BD-I diagnosis, n (%) 
   Manic episode 
   Mixed episode 
 
265 (71.2) 
107 (28.8) 
 
131 (66.5) 
66 (33.5) 
 
269 (68.8) 
122 (31.2) 
 
665 (69.3) 
295 (30.7) 
YMRS Total scorea, mean (SD) 28.8 (6.2) 28.7 (6.2) 29.2 (6.3) 28.9 (6.2) 
MADRS Total scorea, mean (SD) 10.8 (7.0) 12.4 (7.8) 11.3 (7.3) 11.3 (7.3) 
CGI-BP Mania severity scorea, mean 
(SD) 
4.7 (0.8) 4.6 (0.8) 4.6 (0.8) 4.6 (0.8) 
CGI-BP Depression severity scorea, 
mean (SD) 
2.0 (1.2) 2.2 (1.3) 2.1 (1.3) 2.1 (1.3) 
Number of depressive symptomsb, n (%) 
   0–2 
   3 or more 
 
201 (54.0) 
171 (46.0) 
 
100 (50.8) 
97 (49.2) 
 
205 (52.4) 
186 (47.6) 
 
506 (52.7) 
454 (47.3) 
Severity of depressive symptoms, n (%) 
   MADRS Total score <20 
   MADRS Total score ≥20 
 
328 (88.2) 
44 (11.8) 
 
164 (83.2) 
33 (16.8) 
 
338 (86.4) 
53 (13.6) 
 
830 (86.5) 
130 (13.5) 
Anxietyc, n (%) 
   Absent or minimal 
   Present 
   Not rated 
 
144 (38.7) 
227 (61.0) 
1 (0.3) 
 
73 (37.1) 
124 (62.9) 
0 (0.0) 
 
150 (38.4) 
238 (60.9) 
3 (0.8) 
 
367 (38.2) 
589 (61.4) 
4 (0.4) 
Irritabilityd, n (%) 
   Absent or low 
   Present 
   Not rated 
 
150 (40.3) 
218 (58.6) 
4 (1.1) 
 
65 (33.0) 
128 (65.0) 
4 (2.0) 
 
134 (34.3) 
253 (64.7) 
4 (1.0) 
 
349 (36.4) 
599 (62.4) 
12 (1.3) 
Agitatione, n (%) 
   Absent or low 
   Present 
   Not rated 
 
83 (22.3) 
285 (76.6) 
4 (1.1) 
 
48 (24.4) 
145 (73.6) 
4 (2.0) 
 
84 (21.5) 
303 (77.5) 
4 (1.0) 
 
215 (22.4) 
733 (76.4) 
12 (1.3) 
Severe AIAf, n (%) 
   Not present 
   Present 
   One or more symptom not rated 
 
247 (66.4) 
120 (32.3) 
5 (1.3) 
 
123 (62.4) 
70 (35.5) 
4 (2.0) 
 
248 (63.4) 
136 (34.8) 
7 (1.8) 
 
618 (64.4) 
326 (34.0) 
16 (1.7) 
23 
aFor patients missing a value at baseline, the value was used from the screening visit; 562 
bbased on the number of individual MADRS items with a score of ≥1; cbased on the 563 
PANSS anxiety item: ‘absent or minimal’ indicates a score of ≤2; ‘present’ indicates a 564 
score of ≥3; dbased on the YMRS irritability item: ‘absent or low’ indicates a score of ≤3; 565 
‘present’ indicates a score of ≥4; ebased on the YMRS increased motor activity–energy 566 
item: ‘absent or low’ indicates a score of ≤2; ‘present’ indicates a score of ≥3; fmeeting 567 
the above criteria for all three AIA symptoms. 568 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; CGI-BP Clinical Global 569 
Impressions – Bipolar version; DSM-IV Diagnostic and Statistical Manual of Mental 570 
Disorders, Fourth Edition; MADRS Montgomery–Åsberg Depression Rating Scale; PANSS 571 
Positive and Negative Syndrome Scale; SD standard deviation; YMRS Young Mania Rating 572 
Scale.  573 
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Figure captions 574 
Figure 1 575 
Venn diagram displaying the overlap of comorbid AIA symptoms in BD-I mania 576 
Sixteen patients (1.7%) were missing a value for one or more AIA symptom at baseline 577 
and are not shown on the figure. Anxiety was defined as a PANSS anxiety item score of 578 
≥3 at baseline. Irritability was defined as a YMRS irritability item score of ≥4 at baseline. 579 
Agitation was defined as a YMRS increased motor activity–energy item score of ≥3 at 580 
baseline. Percentages are calculated from the full analysis set, which comprised 960 581 
patients. 582 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; PANSS Positive and 583 
Negative Syndrome Scale; YMRS Young Mania Rating Scale. 584 
 585 
Figure 2 586 
Incidence of baseline AIA symptoms in BD-I mania, stratified by the 587 
number/severity of depressive symptoms 588 
**p<0.01, ***p<0.001, chi-squared test. Anxiety was defined as a PANSS anxiety item 589 
score of ≥3 at baseline. Irritability was defined as a YMRS irritability item score of ≥4 at 590 
baseline. Agitation was defined as a YMRS increased motor activity–energy item score of 591 
≥3 at baseline. Severe AIA was defined as meeting the above criteria for all three AIA 592 
symptoms. Patients missing a value for the corresponding symptom at baseline were not 593 
included in the analysis. 594 
aBased on the number of individual MADRS items with a score of ≥1. 595 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; MADRS Montgomery–596 
Åsberg Depression Rating Scale; PANSS Positive and Negative Syndrome Scale; YMRS 597 
Young Mania Rating Scale. 598 
 599 
Figure 3 600 
25 
Incidence of remission in BD-I mania, stratified by baseline AIA/depressive 601 
symptoms 602 
#p-value significant (when adjusted for multiplicity), chi-squared test. Anxiety was 603 
defined as a PANSS anxiety item score of ≥3 at baseline. Irritability was defined as a 604 
YMRS irritability item score of ≥4 at baseline. Agitation was defined as a YMRS increased 605 
motor activity–energy item score of ≥3 at baseline. Severe AIA was defined as meeting 606 
the above criteria for all three AIA symptoms. Patients missing a value for the 607 
corresponding symptom at baseline were not included in the analysis. Two definitions 608 
were used for remission: a YMRS Total score of <12 at Day 21 (upper figures); and a 609 
YMRS Total score of <8 at Day 21 (lower figures) (observed cases). Depressive 610 
symptoms were defined in two ways: ≥3 individual MADRS items with a score of ≥1, or a 611 
MADRS Total score of ≥20 at baseline. 612 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; MADRS Montgomery–613 
Åsberg Depression Rating Scale; PANSS Positive and Negative Syndrome Scale; YMRS 614 
Young Mania Rating Scale. 615 
 616 
Figure 4 617 
Incidence of remission by treatment group in BD-I mania, stratified by baseline 618 
AIA/depressive symptoms 619 
Anxiety was defined as a PANSS anxiety item score of ≥3 at baseline. Irritability was 620 
defined as a YMRS irritability item score of ≥4 at baseline. Agitation was defined as a 621 
YMRS increased motor activity–energy item score of ≥3 at baseline. Severe AIA was 622 
defined as meeting the above criteria for all three AIA symptoms. Patients missing a 623 
value for the corresponding symptom at baseline were not included in the analysis. Two 624 
definitions were used for remission: a YMRS Total score of <12 at Day 21 (upper 625 
figures); and a YMRS Total score of <8 at Day 21 (lower figures) (observed cases). 626 
Depressive symptoms were defined in two ways: ≥3 individual MADRS items with a score 627 
of ≥1, or a MADRS Total score of ≥20 at baseline. 628 
26 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; MADRS Montgomery–629 
Åsberg Depression Rating Scale; PANSS Positive and Negative Syndrome Scale; YMRS 630 
Young Mania Rating Scale. 631 
 632 
Figure 5 633 
Change from baseline in YMRS Total score by treatment group in BD-I mania 634 
*p<0.05, **p<0.01, ***p<0.001 versus placebo, t-test. Anxiety was defined as a PANSS 635 
anxiety item score of ≥3 at baseline. Irritability was defined as a YMRS irritability item 636 
score of ≥4 at baseline. Agitation was defined as a YMRS increased motor activity–energy 637 
item score of ≥3 at baseline. Severe AIA was defined as meeting the above criteria for all 638 
three AIA symptoms. Patients missing a value for the corresponding symptom at baseline 639 
were not included in the analysis. 640 
AIA anxiety, irritability, and agitation; BD-I bipolar I disorder; PANSS Positive and 641 
Negative Syndrome Scale; SE standard error; YMRS Young Mania Rating Scale. 642 
